GlycA: A New Biomarker for Systemic Inflammation and Cardiovascular Disease (CVD) Risk Assessment

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Biomarker Discovery

Background:

• Systemic inflammation is a key factor in cardiovascular disease (CVD) risk.
• Traditional inflammatory biomarkers like hsCRP are used but may have limitations.
• Novel biomarkers are needed for improved CVD risk assessment.

Purpose of the Study:

• To review the GlycA test as a serum biomarker for systemic inflammation and CVD risk.
• To summarize studies on GlycA's predictive value for CVD events and mortality.
• To compare GlycA with established inflammatory biomarkers like hsCRP.

Main Methods:

• Proton nuclear magnetic resonance (¹H-NMR) spectroscopy-based assay (GlycA test).
• Analysis of large cohort studies investigating GlycA levels.
• Correlation analysis with incident CVD events, mortality, and inflammatory markers (hsCRP, IL-6).

Main Results:

• Consistent, moderate positive correlations found between baseline GlycA levels and CVD event rates/mortality.
• GlycA's predictive value remained significant after adjusting for established CVD risk factors and inflammatory biomarkers.
• GlycA demonstrated comparable predictive value to hsCRP for future CVD-related events.

Conclusions:

• The GlycA test is a promising biomarker for systemic inflammation and CVD risk assessment.
• GlycA shows analytical advantages over traditional inflammatory biomarkers.
• Further research is needed to determine clinical utility and indications for GlycA testing.